
Advertise on podcast: The Gut Onc Lab Podcast
Rating
5from
This podcast has
16 episodes
Language
EnglishPublisher
gutonclab1Explicit
No
Date created
2026/02/24
Latest episode
2026/11/06
Average duration
31 min.
Release period
17 days
Description
Dr. Nicholas Hornstein, Udhayvir Grewal, and Dr. Timothy Brown dive into all things oncology related to the gut in these short but info-packed episodes.
Unlock The Gut Onc Lab Podcast podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from The Gut Onc Lab Podcast podcast
Frontline Radioligands: Sparing the Marrow and Moving PRRT Upfront with Dr. Simron Singh
2026/11/06
In this episode of The Gut-Onc Lab, Drs. Nicholas Hornstein and Udhayvir Grewal welcome world-renowned neuroendocrine authority Dr. Simron Singh (Sunnybrook Health Sciences Centre / University of Toronto) to explore why radioligand therapies are undergoing an explosive transformation. Moving from historical nuclear medicine "vibes" into a rigorous oncological trial framework, the panel dissects how the frontline map of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is being entirely redrawn.
Key discussion points include:
The Frontline Shift: Dr. Singh explains the rationale behind the practice-changing NETTER-2 trial—the first randomized trial of radioligand therapy in the first-line metastatic setting for any solid tumor—and its striking 72% reduction in the risk of progression or death for high-grade G2 and G3 well-differentiated tumors.
The SSTR2 Landing Strip: Why PRRT relies entirely on stable somatostatin receptor expression (Krenning 3 or 4 score), and the operational necessity of integrating dual-PET imaging (SSTR-PET + FDG-PET) to calculate a comprehensive NetPET Score.
Sequencing vs. Small Molecules: Analyzing the comparative data from COMPETE and OCCLURANDOM that establishes the clear progression-free survival and health-related quality of life superiority of PRRT over traditional small molecule choices like everolimus or sunitinib.
The Alpha Frontier (ACTION-1): An exclusive preview of the highly anticipated Fall 2026 readout of the Phase III ACTION-1 trial evaluating Actinium-225 labeled dotatate (RYZ101) in patients who have progressed through Lutetium-177, contrasting heavy beta emissions against localized double-stranded DNA breaks.
Therapy-Related Myeloid Neoplasms (TMN): A direct, honest dialogue on the long-term risk of treatment-related MDS and AML, the role of clonal hematopoiesis of indeterminate potential (CHIP), and how sequential alkylating agents alter the marrow baseline.
The 5-Year Vision: Slicing past the limits of a simplistic, static pathology slice toward dynamic 3D tumor mapping, alongside the arrival of DLL3-targeted bispecifics and antibody-drug conjugates (ADCs) for aggressive neuroendocrine carcinomas.
From the hockey analogies of "skating your best player in the first period" to eliminating the logistical 6-hour amino acid chair-time infusion burden, this conversation captures the precision medicine revolution hitting the neuroendocrine landscape.
Chapters:
00:00 PRRT and NETTER-1 Basics
02:08 Why NETTER-2 Went Frontline
04:50 NETTER-2 Results and Impact
05:26 Choosing First Line PRRT
07:56 NETTER-3 for Bulky Low Grade
10:32 Sequencing PRRT vs Other Drugs
14:13 Repeat PRRT and Key Trials
16:53 Dual PET and NetPET Score
20:09 Alpha PRRT Next Wave
25:08 TMN Risk and CHIP Biomarkers
27:35 Toxicities and Mitigation Tips
29:54 Future Outlook and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
ESMO 2026: (Likely) Practice Changing Presentations We’re Excited About
2026/10/22
In this high-velocity conference preview episode of The Gut-Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down to dissect the most anticipated late-breaking abstracts heading into ESMO 2026. Scanning the entire gastrointestinal tract, the panel evaluates high-stakes Phase III data drops, novel antibody-drug conjugates (ADCs), PD-1/VEGF bispecifics, and practice-defining de-escalation strategies.
Key Discussion Points
Upper GI & Claudin 18.2 ADCs:
gHOPE001 (LBA77): Previewing third-line claudin 18.2 ADC efficacy and assessing whether second-generation payloads mitigate historical emetic toxicities.
CLARITY-Gastric-01 (LBA7): Analyzing the Phase III data for sonesi-v (sonidesib tugilimumab) in CLDN 18.2-positive gastroesophageal cancers, contrasting statistically significant overall survival (OS) against missed progression-free survival (PFS) endpoints.
Long-Term SANO (LBA78) & REMIRAS: Evaluating five-year organ preservation data for clinical complete responders in esophageal cancer, alongside final second-line FOLFIRI-RAM vs. Ram-Pac taxane-pretreated outcomes.
Biliary Tract Milestones:
HARMONY-GI001: Evaluating first-line avenasimab (PD-1/VEGF bispecific) plus chemotherapy vs. durvalumab plus chemotherapy in advanced biliary tract cancers.
ACTICA-1 / ActiCCA-1: Predicting whether six months of adjuvant Gemcitabine + Cisplatin (GemCis) will displace capecitabine (BILCAP) as the definitive post-resection standard of care.
Colorectal & MSI-High Landmark Data:
CheckMate-8HW Final OS (LBA32): Examining final overall survival curves for frontline Nivo/Ipi vs. single-agent Nivo and chemotherapy in dMMR/MSI-High metastatic colorectal cancer.
AZUR-1 (LBA37): Reviewing global Phase II dostarlimab monotherapy results in locally advanced dMMR Stage II/III rectal cancer, detailing why a 100% complete clinical response rate renders randomized surgical control trials obsolete.
ECLIPSE Phase II (788ro): Demonstrating why continuing encorafenib + cetuximab beyond progression alongside FOLFIRI prevents MAP-kinase unmasking in BRAF V600E-mutated metastatic colorectal cancer.
Chapters:
00:00 Welcome and Introductions
00:48 Upper GI Preview
00:58 Claudin 18.2 ADC gHOPE001
03:17 CLARITY Gastric 01 Soni V
04:59 SANO Watch and Wait
07:29 REMIRAS Honorable Mention
08:29 Biliary HARMONY GI001 PD1 VEGF
12:51 ACTICA 1 Adjuvant Biliary
17:10 MSI High CRC CheckMate 8HW
20:33 Dostarlimab Rectal Azur 1
25:24 BRAF CRC ECLIPSE Beyond Progression
28:33 More Honorable Mentions and Posters
32:15 Final Thoughts and ESMO Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Integrating Palliative Care Into GI Oncology with Dr. Joseph McCollom
2026/10/08
In this episode of The Gut-Onc Lab, Drs. Nicholas Hornstein and Timothy Brown welcome double-boarded GI oncologist and palliative care specialist Dr. Joseph McCollom (known online as the "Real Bow Tie Doc" from Parkview Health / Packnett Family Cancer Institute). Bringing a unique perspective to the immense symptom burden of GI malignancies, Dr. McCollom explores how treating cancer and providing supportive care are not sequential steps, but rather "two doors to the same hallway."
Key Discussion Points
The 21st-Century Bowtie Model: Moving away from the outdated paradigm of reserving palliative care exclusively for end-of-life transitions. Dr. McCollum breaks down Dr. Pippa Hawley’s dual-triangle framework, illustrating how supportive care runs concurrently with disease-directed treatment—extending into curative survivorship, managing chronic toxicities, and navigating advanced metastatic care.
The "Cloak" Elevator Pitch: Defining palliation from its Latin root (palliare, to cover or cloak)—reminding clinicians and patients that while chemotherapy attempts to change the "weather" (disease course), palliative care acts as the coat protecting the patient through the storm.
Personalized Palliative Care: Shifting away from rigid, stage-based referral algorithms toward individualized clinical intuition—using validated tools like the "Surprise Question" ("Would I be surprised if this patient were not here next year?") to trigger supportive interventions early.
Restoring Dignity & Meaning: Looking beyond basic numerical survival curves to combat existential distress. The panel discusses emerging non-pharmacologic and creative modalities—from psilocybin-guided journeys to virtual reality (VR) immersive experiences in infusion suites—to maintain patient autonomy.
Physician Burnout & Institutional Humanism: Dr. McCollum reflects on his personal journey from the foster care system to dual subspecialization, highlighting institutional strategies to combat grief and burnout—such as solemn "Reading of the Names" monthly ceremonies.
Chapters:
00:00 Welcome and Introductions
01:53 Why Palliative Care Matters
02:32 Bow Tie Model Explained
06:13 Palliative Care Elevator Pitch
07:18 Future of Palliative Oncology
09:56 Cancer Pain and Methadone
14:28 When to Refer Patients
18:40 Barriers and Misconceptions
22:34 Meaning Dignity and New Tools
26:17 Burnout and Staying Fulfilled
31:47 Closing Thanks and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
The POD1UM-303 Triumph: Retifalimab, Mitomycin Toxicity, and Frontline Anal Oncology
2026/09/09
In this episode of The Gut-Onc Collab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal dive into a disease site currently undergoing a massive therapeutic shift: anal cancer. As an inherently HPV- and HIV-associated malignancy, managing anal squamous cell carcinoma demands rigorous multidisciplinary staging, careful toxicological navigation, and an understanding of newly minted frontline survival data.
Key highlights from the discussion include:
The Diagnostic Checklist: Establishing the modern staging workflow—from digital rectal examinations and pelvic MRIs to the mandatory role of early PET/CT and universal HIV screening to preserve marrow baseline parameters.
The Nigro Protocol Legacy: Honoring the 1970s Wayne State breakthrough that pioneered organ preservation in solid tumors, demonstrating that 5-FU and mitomycin C combined with radiation could reliably cure patients without sacrificing the anal sphincter.
The Great Cisplatin Debate: Dissecting the trial data from ACT II and RTOG 9811 to weigh mitomycin’s long-term myelotoxicity risks against the non-inferior survival curves of weekly low-dose cisplatin backbones.
Drawing the Curative Line: Mapping out tumor board thresholds—why inguinal and pelvic lymph nodes demand aggressive, definitive chemoradiation, while para-aortic involvement above the diaphragm signals a transition to systemic therapy.
The POD1UM-303 / INTERACT2 Landmark: Breaking down the Phase III data combining carboplatin and paclitaxel with the PD-1 inhibitor retifanlimab. The team explores the drug’s massive duration of response doubling (from 7 to 14 months) and its recent definitive overall survival (OS) victory in all-comers, completely independent of baseline PD-L1 expression.
From historical chemotherapy milestones to managing immune-related adverse events in patients on antiretroviral therapy, this episode serves as a definitive clinical blueprint for modern anal cancer care.
Chapters:
00:00 Why Anal Cancer Now
01:08 Initial Workup and Staging
03:01 HPV HIV Testing Basics
04:19 Nigro Protocol Origins
06:05 Mitomycin vs Cisplatin
09:54 Defining Metastatic Boundaries
11:40 New First Line Metastatic Data
13:57 Toxicity Biomarkers HIV Safety
15:11 Key Takeaways and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Curative Intent in CRLM: Surgery, ctDNA, and the Biology of Liver Metastases
2026/08/25
In this episode of The Gut-Onc Lab, Drs. Nicholas Hornstein and Timothy Brown welcome renowned HPB and surgical oncologist Dr. Robert Martin (University of Louisville) to dismantle the management of colorectal cancer liver metastases. While metastatic colorectal cancer carries a heavy prognosis overall, oligometastatic liver-limited disease represents a unique, potentially curable window when local interventions and systemic therapies are deployed in tandem.
Key discussion points include:
Optimism vs. Biology: Dr. Martin shares his 26-year perspective on why two-thirds of resected patients eventually recur, and how classic risk tools like the Fong Score combine with molecular drivers (BRAF and KRAS mutations) to dictate surgical timing.
The "Simple First" Rule: How to prioritize combined operations when managing an intact primary alongside liver metastases, minimizing chemotherapy washout windows to keep patients fit and functional.
The Perioperative Debate: Analyzing why solitary, long-interval metastases can go straight to the operating room, while high-risk node-positive or BRAF-mutated tumors require a perioperative chemotherapy "tincture of time" to prevent futile surgeries.
The GALAXY / JAMA Oncology Data: A deep dive into the 2026 JAMA Oncology analysis of 298 CRLM patients from the CIRCULATE-Japan registry. The team analyzes why post-op MRD positivity carries a massive hazard ratio (>9) for overall survival, why adjuvant chemo significantly improves survival in upfront-surgery MRD-positive patients, and why neoadjuvant-pretreated patients derive no added benefit from post-op chemo regardless of ctDNA status.
The "Two-Point" ctDNA Rule: Why Dr. Martin advocates for repeating a positive ctDNA test at 4 and 6 weeks post-op before declaring minimal residual disease, using temporal kinetics to guide diagnostic MRI intensity rather than jumping directly to futile cytotoxic escalation.
From avoiding "gut-punch" recurrences to refining chemo-free holidays for MRD-negative patients, this session provides a comprehensive blueprint for the modern, multidisciplinary management of liver-limited colorectal cancer.
Chapters:
00:00 Welcome and Introductions
01:23 Why Liver Mets Matter
02:35 Assessing Biology and Risk
04:10 Choosing Local Therapies
08:18 Primary vs Liver Timing
11:05 Perioperative Chemo Strategy
14:10 ctDNA Basics and Use
16:47 Galaxy Data and Chemo Debate
21:32 Managing MRD Positive Patients
23:11 Future Trials and Kinetics
27:07 Tumor Board and Next Five Years
30:07 Key Takeaways and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Systemic Therapies in HCC: Immunotherapy and Beyond with Mark Yarchoan
2026/08/07
In this episode of The Gut-Onc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome physician-scientist Dr. Mark Yarchoan (Johns Hopkins / Sidney Kimmel Comprehensive Cancer Center) to navigate the rapid evolution of hepatocellular carcinoma (HCC) management. Moving away from the era when single-agent TKIs offer limited survival extension at high toxicity costs, the panel outlines how modern immune checkpoint combinations and redefined staging guidelines are transforming clinical expectations.
Key discussion points include:
The Frontline IO Framework: Dr. Yarchoan details his decision matrix for choosing between the three primary frontline combinations:
Second-Line Sequencing Realities: Why TKI-naive post-IO patients should transition to frontline-caliber TKIs (like lenvatinib), while atezo/bev progressors derive long-term durability from CTLA-4 salvage doublets (Ipi/Nivo) if they suffered primary non-response.
Updating the Staging Paradigm (BEACON vs. BCLC): Why the classic Barcelona Clinic Liver Cancer (BCLC) system over-simplifies micro-vascular invasion as non-curable, and how the emerging BEACON guidelines incorporate SBRT, Y-90, and multidisciplinary down-staging pathways.
Post-ASCO 2026 Local-Regional Updates: Analyzing EMERALD-3 and ABC-HCC—explaining why administering dual checkpoint immunotherapy before TACE preserves the tumor microenvironment for superior antigen presentation, and why TACE is increasingly shifting toward oligoprogressive control rather than diffuse intermediate-stage deployment.
The Histotripsy Reality Check: A candid evaluation of non-invasive ultrasound cavitation, contrasting Facebook marketing claims against the HOPE Liver trial data regarding high local failure rates, treatment-related mortality, and general anesthesia requirements compared to established microwave ablation.
Chapters:
00:00 HCC Treatment History
02:40 Life in the Sorafenib Era
04:35 Immunotherapy Breakthroughs
07:29 Choosing First-Line Therapy
14:01 Second Line Strategy
20:00 Staging Beyond BCLC
24:42 ASCO 26 TACE Combinations
30:36 Neoadjuvant Timing Insights
32:18 Histotripsy Hype vs Data
35:03 Closing Thoughts and Trials
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Approaching Clinical Trials As A Patient, What To Know.
2026/08/03
In this special foundational episode of The Gut-Onc Collab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal step back from individual disease sites to pull back the curtain on clinical trials. As the literal engines of modern oncology, trials bridge the gap between bench discovery and real-world clinic operations. The panel outlines everything from the hidden logistics of study startups to the nuances of statistical endpoints, providing a comprehensive guide for both patients and clinicians.
Key highlights from the discussion include:
Dismantling the Trial Phases: A clear breakdown of the structural ladder—from Phase I safety dose-escalation (RP2D) and intensive pharmacokinetic (PK) blood draws to Phase II exploratory signals and Phase III randomized comparative endpoints.
The Clinical Validity Trap: Tim analyzes why "cherry-picking" hyper-fit, idealized trial populations harms external validity, explaining why study groups must mirror the diverse lab values of actual community clinics.
Critiquing the Literature (An Oncologist's Lens): Udhayvir shares his method for analyzing fresh publications—scrutinizing whether control arms are substandard, tracking how protocol amendments pivot to shifting standards, and evaluating when to look past PFS surrogate lines to demand Overall Survival (OS) clarity.
Navigating "Time Toxicity" & Burden: A realistic assessment of patient commitment—how standard clinic visits transform into prolonged multi-staff interactions, and how patients maintain agency under randomized computer control.
Early-Career PI Survival Guide: Practical parameters for new site investigators, including managing study-startup pipelines, navigating site initiation visits (SIVs), and leveraging senior institutional mentors.
Modern Scouting Tools: Spotlighting user-centric discovery methods—from utilizing advanced AI agents to scrape ClinicalTrials.gov to partnering with premiere advocacy networks like PanCAN, the Colorectal Cancer Alliance (Colon Town), and NETRF.
From evaluating adverse events using Lexicomp and NEJM snapshots to understanding the unique tracking exceptions of rare, indolent neuroendocrine cancers, this episode serves as the definitive primer for the entire framework of modern oncology research.
Chapters:
00:00 Why Clinical Trials Matter
01:36 Phase 1 Basics and Safety
03:14 Phase 1 Patient Burden and Upside
05:31 Phase 2 Proving Activity
07:39 Phase 3 Standards Randomization
09:53 Choosing and Judging Trials
15:00 Patient Commitment and Toxicity
17:50 Becoming a Trial Investigator
19:48 Finding Trials and Advocacy
22:25 Final Takeaways and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
The Gut-Onc Collab: Universal Testing Laws, BRCA1 Discordance, and the RAS Wave with Dr. Kim Reiss
2026/07/09
On this in-person episode of The Gut Onc Lab podcast, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome world-renowned BRCA specialist Dr. Kim Reiss to dismantle the historic view of pancreatic cancer as a monolithic, chemo-only disease. The group dives deep into the 5% to 9% of pancreatic ductal adenocarcinoma (PDAC) patients harboring germline or somatic homologous recombination repair (HRR) defects and how to maximize their survival.
Key discussion points include:
First-Line Crosscurrents: Why the team remains FOLFIRINOX traditionalists over the newly approved NAPOLI-3 Nalirifox regimen, and the operational reality that universal testing must start at day zero.
The APOLLO Trial Blueprint: Dr. Reiss details the international Phase III ECOG-ACRIN EA2192 trial—mirroring breast cancer's landmark Olympia study—bringing a year of adjuvant olaparib maintenance into the curative-intent space.
Brainwashing Fellows & Hunting Rare Variants: Raw advice for junior investigators on leveraging advocacy groups, social media, and temporal NGS tracking to keep specialized clinical trials accruing.
The BRCA1 vs. BRCA2 Paradox: Dissecting Dr. Talia Golan’s Cancer Discovery data revealing why 50% of BRCA1 pancreatic tumors are actually sporadic bystander events, compared to the 90% true biallelic loss seen in BRCA2.
Dismantling Negative Data: A critical look at SWOG 2001 and the European durvalumab/olaparib updates, explaining why adding immunotherapy to PARP inhibitors failed broadly across all-comers unless a specific T-cell inflamed microenvironment is isolated.
The Golden Era of Targeted PDAC: Looking past the immediate RASolute-302 pan-RAS plenary drop to the fast-approaching pipelines of Claudin 18.2 combinations and MTAP-deletion / PRMT5 inhibitors.
From the immediate necessity of split-dose Cis-Gem pivots to a world where targeted pills dominate frontline care, this conversation frames the exact moment pancreatic oncology permanently moved into the precision era.
Chapters
(00:00) Why Pancreatic Cancer Needs Better Options
(01:29) First Line Chemo Choices Today
(02:33) Testing and When to Pivot
(04:19) Subtype Assays and Practical Limits
(05:59) POLO and PARP Maintenance Lessons
(07:49) APOLLO Trial Design and Progress
(09:28) Recruiting Rare Variant Patients
(11:34) Standard Care for BRCA PALB2
(12:13) BRCA1 vs BRCA2 Biology and HRD
(13:48) ASCO Outlook and KRAS Era
(15:54) PARP Plus Immunotherapy Biomarkers
(19:12) Closing Thoughts and RAS Revolution
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
The Precision Shift: Re-Writing the Colorectal Cancer Roadmap with Dr. Arvind Dasari
2026/06/22
In this special in-person episode filmed straight from the floor at ASCO 2026, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal welcome guest Dr. Arvind Dasari (MD Anderson) to discuss why colorectal cancer is officially having its precision medicine moment. From the epidemic of young-onset disease to the frontline tracking of ultra-specific biomarkers, the panel discusses why molecular profiling is now just as critical as a histological diagnosis.
Key discussion points include:
Universal Testing & The ALASCCA Data: Why every patient—localized or metastatic—requires immediate biomarker staging, including a look at using adjuvant aspirin to target PI3K/PTEN/PIK3CA pathway alterations.
The CIRCULATE-North America Blueprint: Dr. Dasari shares the technical and regulatory hurdles of designing a major serial ctDNA trial, the removal of the Phase II/III FDA hold, and how the study is dynamically expanding eligibility rules for stage III de-escalation.
The Turnaround Revolution: A practical look at clinic operations in 2026—how combining liquid biopsy with fast-tracked DPYD and UGT1A1 panels delivers actionable genomic results in under seven days.
Targeting the Known Frontiers: Breaking down the current state of BREAKWATER (BRAF V600E), CheckMate 8HW (Nivo/Ipi doublets in dMMR), and the downstream nuances of RAS co-occurrence in HER2-targeted therapies vs. ADCs.
Post-Conference Takeaways: The panel's real-time analysis of the major ASCO abstracts, including the Dutch PUMP trial (adjuvant hepatic artery infusion pumps for liver metastases) and the data validating the cessation of immunotherapy for complete responders.
From institutional operator expertise in HAI pumps to the future of "unknown target" molecular glues, this session bridges the gap between massive data drops and Monday morning clinic realities.
Chapters:
(00:00) Welcome and Introductions
(00:54) Meet Dr Dasari
(04:15) Who Gets Molecular Testing
(07:41) CIRCULATE Trial Explained
(09:00) Trial Design Challenges
(14:11) Whats Next in CRC Therapy
(16:16) HER2 Positive Approach
(17:02) ASCO Highlights and Practice Changers
(18:43) Nonoperative and Supportive Care
(20:25) HAI Pump PUMP Study
(21:45) Closing Thoughts and Sign Off
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
ASCO 2026: GI Oncology Abstracts to Look Forward To.
2026/05/26
With the 2026 ASCO Annual Meeting just days away, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down for a rapid-fire, "mouth-to-butt" preview of the most practice-altering abstracts hitting the floor in Chicago. Armed with top-line press releases and early data, the team highlights their top three high-stakes selections across the entire GI tract.
Key previews include:
The Upper GI Blockbusters (Tim’s Picks): Updated HORIZON-GEA data showing why HER2/PD-1 bispecific synergy doesn't care about baseline PD-L1 expression; a compliance deep-dive from the Matterhorn trial; and the arrival of IsaBrin (an EGFR/HER3 bispecific ADC) moving the needle in second-line squamous cell esophageal cancer.
The Midgut & Plenary Hype (Udhayvir’s Picks): Front-row seats for RESOLUTE-302, the monumental plenary session showcasing deruxantrib doubling overall survival (13 months vs. 6.7 months) in second-line RAS-mutant pancreatic cancer. Plus, the PHITE-302 trial proving frontline pemigatinib works for FGFR2-rearranged cholangiocarcinoma despite notorious accrual challenges.
Below-the-Belt Tech & Wild West De-escalation (Nick’s Picks): The highly anticipated late-breaking PUMP trial testing adjuvant hepatic artery infusion (HAI) pumps for colorectal liver metastases. Then, a massive look at China's Abstract 3502, confirming that MSI-High colorectal patients who hit a Complete Clinical Response can safely stop maintenance immunotherapy and maintain a 100% 3-year overall survival rate.
The Sci-Fi Future: A look outside the box at the Archer trial in lung cancer—utilizing a prophylactic peptide vaccine to train the immune system to short-circuit targeted therapy resistance mutations before they occur.
Chapters:
(00:00) Welcome and ASCO Preview
(00:46) Top Three Picks Setup
(01:28) HORIZON GEA HER2 Triplet
(03:55) Matterhorn DFLOT Completion
(06:11) IsaBrin for ESCC Second Line
(08:10) RESOLUTE-302 RAS Inhibitor
(13:12) PHITE 302 Pemigatinib Frontline
(20:10) PUMP Trial Hepatic Infusion
(24:02) MSI-High CRC Stop PD-1
(29:15) Archer Vaccine vs Resistance
(33:30) Closing Thoughts and Chicago
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Organ Preservation in Upper GI Cancers
2026/05/15
In this landmark fifth episode of The Gut Onc Lab, Drs. Nicholas Hornstein and Timothy Brown welcome their first guest, radiation oncologist Dr. Nina Sanford, to discuss one of the most significant shifts in modern oncology: Organ Preservation. Historically, esophageal and gastric cancers have required highly morbid, "life-changing" surgeries. Today, the team explores how we can leverage advanced imaging, radiation, and immunotherapy to potentially spare the organ without sacrificing survival.
Key highlights include:
Defining Organ Preservation: Why avoiding esophagectomy or gastrectomy is the goal, provided we maintain oncologic outcomes.
The SANO Trial Deep Dive: A look at the Phase 3 data establishing "Watch and Wait" as a non-inferior strategy for complete responders, and the modeling studies that suggest where surgery might still pull ahead long-term.
The MSI-High Exception: How medical oncology is leading the way with chemo-free immunotherapy (PD-1 and CTLA-4 doublets) to achieve near-miraculous clinical complete responses in a subset of patients.
Radiation as a Biological Tool: Dr. Sanford explains why "one-size-fits-all" radiation is a thing of the past.
The Burden of Surveillance: A realistic look at "Time Toxicity"—the intensive endoscopy, PET, and CT schedules required to safely manage patients who forgo surgery.
Multidisciplinary Buy-In: Why organ preservation isn't just about biology; it’s about having a surgical team ready for "salvage" and a GI team dedicated to frequent monitoring.
Whether you're curious about the biological "Magic Rays" of radiation or the latest "Infinity" and "NEONIKA" trial results, this episode defines the current frontier of upper GI sparing.
Chapters:
(00:00) Why Organ Preservation Matters
(03:48) Immunotherapy Enters the Chat
(06:45) Key Evidence for Watch and Wait
(09:45) Quality of Life and Long Term Tradeoffs
(13:10) Radiation Dose and Adaptive Future
(17:32) Cross vs FLOT and RT in Gastric
(20:38) MSI High Chemo Free Pathway
(26:48) Surveillance Protocols and Logistics
(28:23) Ideal Candidates and Feasibility
(31:43) Infrastructure for Community Practice
(33:03) Final Takeaways and Wrap Up
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
MSI-High in GI Oncology: When Biology Opens the Door
2026/04/27
In this episode of The GutOnc Lab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal break down MSI-High GI cancers. A cancer diagnosis is never good news—but this is a setting where tumor biology meaningfully changes what’s possible, with immunotherapy offering real potential for durable responses and even cure.
Key discussion points include:
MMR vs. MSI: A diagnostic primer on the difference between IHC (protein) and NGS/PCR (molecular), including how to handle the discordance.
The “Parachute” Data: Breaking down the practice-changing CheckMate 8HW results—and why a hazard ratio of 0.21 is hard to ignore. Nick walks through why nivo/ipi is increasingly his frontline default.
The COMMIT Curveball: Why the COMMIT trial data didn’t deliver—and what it may tell us about PD-L1 vs PD-1 strategies in colorectal cancer.
Pseudoprogression vs Hyperprogression: Tim shares practical, in-the-clinic ways to tell whether a scan is showing immune infiltration… or true disease acceleration.
ctDNA at 6 Weeks: How Nick uses early ctDNA dynamics as a real-time readout of response—especially when you’re pushing toward non-operative management.
When IO Fails: What next? From CTLA-4 “immune salvage” approaches to where targeted therapy (including BRAF-directed options) fits.
Whether you’re screening for Lynch or choosing between single-agent PD-1 and dual checkpoint blockade, this episode covers how we’re actually managing dMMR/MSI-H disease right now.
Chapters:
(00:00) MSI High Basics
(02:31) MSI vs MMR Methods
(05:12) Choosing Tests in Practice
(09:59) TMB Pitfalls
(12:14) Pivotal Immunotherapy Trials
(15:13) CheckMate 8HW Results
(21:03) Biomarkers for Ipi Nivo
(25:47) PD1 vs PDL1 Debate
(31:52) Using ctDNA in Practice
(34:42) How Long to Treat
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Pancreatic Cancer Breakthrough: The Pan-RAS Inhibition Era
2026/04/16
Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal break down the blockbuster press release from Revolution Medicine regarding their Phase 3 trial, RASOLUTE 302. For years, KRAS was the "compact, smooth" molecule that defied targeted therapy, but the era of the molecular glue has officially arrived.
Understanding the Breakthrough:
The hosts emphasize the shift from "OFF" inhibitors to "ON" inhibitors. The following visual concept illustrates how these new molecular glues utilize a chaperone to finally lock onto the active state of the KRAS protein.
Chapters:
00:00 Press Release Breakthrough
01:21 Why KRAS Was Undruggable
03:14 Limits of G12C Inhibitors
08:43 Trial Results
13:58 What It Means for Patients
20:30 Oncoderm and Support Team
20:56 Whats Next in Trials
You can find us on X: Gut Onc Lab (@TheGutOncLab) / X
Claudin 18.2 in Upper GI Cancer: New Target, New Challenges
2026/04/01
Drs. Hornstein, Brown, and Grewal discuss how Claudin 18.2 has quickly become an important actionable biomarker in upper GI cancers, with zolbetuximab now entering frontline treatment for selected HER2-negative, microsatellite-stable patients. They review the key phase 3 data supporting its use, while emphasizing that the major challenge in practice is managing the significant nausea and vomiting seen early in treatment. The conversation also highlights how biomarker sequencing now shapes therapy selection and how future strategies, including ADCs, CAR T-cell therapy, and immunotherapy combinations, may further expand the role of Claudin 18.2 targeting.
Evolving Strategies in Upper GI Cancer Ep 02.
2026/03/14
In the second episode of The Gut-Onc Collab, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal tackle the explosive growth of targeted therapies in the Upper GI space. The team dives deep into the "how" and "when" of treating HER2-positive and HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinomas, moving from perioperative care to the second-line setting.
Key Takeaways:
The Matterhorn Trial: Why adding Durvalumab to perioperative FLOT is an immediate practice-changer for resectable gastric/GEJ cancer, and the team’s "oncologist vs. purist" debate on extrapolating this to esophageal patients.
Destiny-Gastric 04 (DG04): A look at Trastuzumab Deruxtecan (T-DXd) displacing the long-standing "Ram-Pac" regimen in the second line. The hosts share raw clinical experiences with its toxicity profile and why it is not "Trastuzumab 2.0."
Horizon-GEA 01 & Zanidatamab: Analyzing the bispecific antibody that broke the 2-year median OS barrier. The team critiques the trial’s controversial control arm while acknowledging the undeniable "ball don't lie" efficacy data.
Clinical Pearls: The necessity of repeat biopsies, the rise of liquid biopsy in monitoring HER2 status, and the "loperamide trick" for managing zanidatamab-induced diarrhea.
From precision oncology to "triple-prophylaxis" anti-emetic strategies, this episode provides a roadmap for the modern management of Upper GI malignancies.
Chapters:
(00:00) Matterhorn Trial Overview
(05:38) Results and Impact
(10:29) How Long to Treat
(15:25) TDXd vs RamPac Results
(16:05) TDXd Toxicity and Dosing
(20:28) Liquid Biopsy Questions
(21:16) Horizon GEA01 Setup
(26:07) Results That Shift Care
(32:58) Infusion Reaction Basics
(35:17) Closing Reflections
Podcast sponsorship advertising
Start advertising on The Gut Onc Lab Podcast relevant audience podcasts
You may also like to advertise on these Podcasts

4.41171483
The Outlier Health Podcast
Matt Frazier, Matt Tullman, Isabelle Caputo, and Doug Hay

4.616215365
Giggly Squad
Hannah Berner & Paige DeSorbo

4.8219787
Imperfect Action
Steph Taylor

4.727637592
This Past Weekend w/ Theo Von
Theo Von

4.713055379
The Tim Dillon Show
The Tim Dillon Show

4.116091470
The Tucker Carlson Show
Tucker Carlson Network

4.828116459
Huberman Lab
Scicomm Media

4.240683
To Be The Man
Podcast Heat | Cumulus Podcast Network

4.41511782000
The Ben Shapiro Show
The Daily Wire

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network